Stocks · News reference
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 125 percent decrease over losses of $(0.04) per share from the same period last year.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court
Read original at benzingaFiled: 2026-08-05 AccNo: 0001193125-26-335212 Size: 280 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarCytek Biosciences (NASDAQ:CTKB) raises FY2026 sales outlook from $205.000 million-$212.000 million to $207.000 million-$212.000 million vs $208.767 million estimate.
Read original at benzinga